LOX-1 in atherosclerotic disease

Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting

“…29,32 Ezetimibe inhibits cholesterol absorption; in contrast, statin monotherapy enhances it (Table II in In this study, ezetimibe administered with statins significantly decreased oxysterol levels, along with LDL-C and MDA-LDL levels, in the E+S arm. In addition, among the subgroups with equivalent LDL-C levels, total oxysterol levels were still significantly decreased in the E+S arm (Table III in the onlineonly Data Supplement).…”

“…Endothelial dysfunction in hypercholesterolemia is attributed primarily to oxidized LDL, which has been shown to decrease NO bioavailability in endothelial cells through the inhibition of the expression of NO synthase 28 and the production of reactive oxygen species via the lectin-like oxidized LDL receptor (LOX-1). 29 Among several indicators of oxidized LDL, MDA-LDL represents malondialdehyde-induced modifications of apolipoprotein B 30 and is associated with endothelial dysfunction. 31 Therefore, lipid-lowering therapies per se improve endothelial function at least in part through decreasing the levels of oxidized LDL.…”

“…31 Therefore, lipid-lowering therapies per se improve endothelial function at least in part through decreasing the levels of oxidized LDL. 29,32 Ezetimibe inhibits cholesterol absorption; in contrast, statin monotherapy enhances it (Table II in the online-only Data Supplement). Although markers of high rates of cholesterol absorption are associated with a high risk of cardiovascularrelated mortality among patients with similar LDL-C levels, 8 34 demonstrated the additional effects of ezetimibe on reducing coronary plaque volume when coadministered with statin, especially in acute coronary syndrome patients, and noted the effect of ezetimibe beyond lowering LDL-C with changes in the levels of markers of cholesterol absorption.…”

Developmental Endothelial Locus-1 (Del-1) Inhibits Oxidized Low-Density Lipoprotein Activity by Direct Binding, and Its Overexpression Attenuates Atherogenesis in Mice

“…13-16, 37 At the time of those reports, the presence of anti-oxLDL factors demonstrated here had not yet been considered. The strong predictive relationship between LAB and cardiovascular risk, however, suggests that a similar mechanism might also be working in humans.…”

Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer

“…LOX-1, which facilitates binding, internalization and degradation of oxidized LDL in endothelial cells, can lead to endothelial dysfunction and may play a role in the pathogenesis of atherosclerosis [14]. sLOX-1 has been accepted as a novel marker for atherosclerosis [15].…”